Skip to main content
Terug
Watch Compare

Apimeds Pharmaceuticals US, Inc.

Datakwaliteit: 83%
APUS
NYSE Manufacturing Chemicals
€ 1,88
€ 0,00 (0,00%)
Marktkapitalisatie: 23,64 M
Prijs
€ 1,88
Marktkapitalisatie
23,64 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -5,88 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-69,68%
Onder sectorgemiddelde (-54,01%)
ROIC-54,27%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,34
Interest Coverage-33,21

Waardering

PE (TTM)
-3,79
Onder sectorgemiddelde (-1,49)
P/B Ratio2,90
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -3,8 -1,5
P/B 2,9 1,6
ROE % -69,7 -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -6,24 M
ROE -69,68% ROA -63,00%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5,88 M
ROIC -54,27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,34
Interest Coverage -33,21 Asset Turnover N/A
Working Capital 8,00 M Tangible Book Value 8,16 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,79 Forward P/E N/A
P/B Ratio 2,90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24,86%
Market Cap 23,64 M Enterprise Value 16,66 M
Per Share
EPS (Diluted TTM) -0,65 Revenue / Share N/A
FCF / Share -0,47 OCF / Share -0,46
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 94,25%
SBC-Adj. FCF -5,95 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024
Revenue —
Net Income -1,39 M
EPS (Diluted) -0,18
Gross Profit —
Operating Income -1,28 M
EBITDA —
R&D Expenses 98.544,0
SG&A Expenses —
D&A —
Interest Expense 117.719,0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2024
Total Assets 13.057,0
Total Liabilities 1,37 M
Shareholders' Equity -1,36 M
Total Debt 20.000,0
Cash & Equivalents 3.455,0
Current Assets 13.057,0
Current Liabilities 1,02 M